Summary
To perform an epidemiological evaluation of the predictive value of p53 autoantibodies in breast cancer, we measured antibodies against p53 in serum samples from 165 breast cancer patients in comparison with serum samples from 330 healthy controls, selected from the same population as the cases and matched for age, sex and specimen storage time. Median age of patients was 51 years (range 25–64 years). Presence of serum p53 autoantibodies was analysed by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blotting. The lower ELISA reactivities were similar for cases and controls, but presence of high-level reactivity was more common among cases than among controls [odds ratio (OR) 9.03, 95% confidence interval (CI) 2.40–50.43]. Presence of Western blot-detected p53 autoantibodies had a very similar association (OR 10.8, CI 3.0–59.4). Among the cases, we also studied whether there was any correlation between level of anti-p53 antibodies and stage of the disease or survival. There was no significant correlation between presence of antibodies and stage of the disease. There was a significant negative correlation between presence of p53 antibodies and survival (P= 0.003). A stepwise multivariate Cox regression analysis showed that T-stage, age and presence of anti-p53 antibodies were significant independent prognostic variables, with a dose-dependent negative effect on survival for all three variables. We conclude that presence of anti-p53 antibodies are of significance both for the risk of having breast cancer and the risk of dying from breast cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K. & Mcguire, W. L. (1993a). Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206.
Allred, D. C., Clark, G. M., Fuqua, S. A. W., Elledge, R. M., Hilsenbeck, S. G., Ravdin, P. M., Yee, D., Chamness, G. C. & Osborne, C. K. (1993b). Overexpression of p53 in node-positive breast cancer. Breast Cancer Res Treat 27: 131
Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A. & Millis, R. R. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?. Hum Pathol 24: 469–476.
Coomber, D., Hawkins, N. J., Clark, M., Meagher, A. & Ward, R. L. (1996). Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122: 757–762.
Crawford, L. V., Pim, D. C. & Bulbrook, R. D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403–408.
Davidoff, A. M., Kerns, B. J. M., Iglehart, J. D. & Marks, J. R. (1991a). Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51: 2605–2610.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D. & Marks, J. R. (1991b). Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010.
Davidoff, A. M., Iglehart, J. D. & Marks, J. R. (1992). Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439–3442.
Green, J. A., Mudenda, B., Jenkins, J., Leinster, S. J., Tarunina, M., Green, B. & Robertson, L. (1994). Serum p53 autoantibodies: incidence in familial breast cancer. Eur J Cancer 30A: 580–584.
Hanzal, E., Gitsch, G., Kohlberger, P., Dadak, C. H., Miechowiecka, N. & Breitenecker, G. (1992). Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Anticancer Res 12: 2325–2330.
Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. (1991). p53 mutations in human cancers. Science 253: 252–254.
Houbiers, J. G. A., van der Burg, S. H., van de Watering, L. M. G., Tollenaar, RAEM, Brand, A., van de Velde, C. J. H. & Melief, C. J. M. (1995). Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637–641.
Isola, J., Visakorpi, T., Holli, K. & Kallioniemi, O-P (1992). Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114.
Labrecque, S., Naor, N., Thomson, D. & Matlashewski, G. (1993). Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468–3471.
Lane, D. P. & Benchimol, S. (1990). p53: oncogene or anti-oncogene. Genes Dev 4: 1–8.
Lubin, R., Schlichtholz, B., Teillaud, J. L., Garay, E., Bussel, A., Wild, C. P. & Soussi, T. (1995). p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin Cancer Res 1: 1463–1469.
Mudenda, B., Green, J. A., Green, B., Jenkins, J. R., Robertson, L., Tarunina, M. & Leinster, S. J. (1994). The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115–1119.
Noguchi, M., Kitagawa, H., Kinoshita, K., Miyazaki, I., Saito, Y. & Mizukami, Y. (1993). Prognostic significance of p53 and c-erbB-2 experience in operable breast cancer. Int J Oncol (Greece) 2: 587–591.
Osborne, R. J., Merlo, G. R., Mitsudomi, T., Venesio, T., Liscia, D. S., Cappa, A. P. M., Chiba, I., Takahashi, T., Nau, M. M., Callahan, R. & Minna, J. D. (1991). Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194–6198.
Ostrowski, J. L., Sawan, A., Henry, L., Wright, C., Henry, J. A., Hennessy, C., Lennard, J. W., Angus, B. & Horne, H. W. (1991). p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75–81.
Peyrat, J. P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J. & Soussi, T. (1995). Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621–622.
Porzolt, F. M. S., Hoher, D., Muche, D., Gaus, W. & Montenarth, M. (1994). Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 17: 402–408.
Regidor, P. A., Regidor, M., Callies, R. & Schindler, A. E. (1996). Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur J Gyanaecol Oncol 17: 192–199.
Ryder, S. D., Rizzi, P. M., Volkmann, M., Metivier, E., Pereira, L. M., Galle, P. R., Naoumov, N. V., Zentgraf, H. & Williams, R. (1996). Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 49: 295–299.
Schlichtholz, B., Legros, Y. & Gillet, D. (1992). The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380–6384.
Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G. & Veronesi, U. (1993). p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965–970.
Stenmark-Askmalm, M., Stål, O., Sulliwan, S., Ferraud, L., Xiao-Feng, S., Carstensen, J. & Nordenskjöld, B. (1994). Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 30A: 175–180.
Thor, A. D., Moore, D. H. I., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L-C, Mayall, B. H. & Smith, H. S. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845–855.
UICC (1982). TNM Classification of Malignant Tumours, 3rd edn. Springer Verlag: Geneva
Vojtesek, B., Kovarik, J., Dolezalova, H., Nenutil, R., Havlis, P., Brentani, R. R. & Lane, D. P. (1995). Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 71: 1253–1256.
Willsher, P. C., Pinder, S. E., Robertson, L., Nicholson, R. I., Ellis, I. O., Bell, J. A., Blamey, R. W., Green, J. A. & Robertson, J. F. (1996). The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16: 927–930.
Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F. & Carbone, D. P. (1992). Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168–4174.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Lenner, P., Wiklund, F., Emdin, S. et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 79, 927–932 (1999). https://doi.org/10.1038/sj.bjc.6690148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690148
Keywords
This article is cited by
-
Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis
Systematic Reviews (2022)
-
Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters
Endocrine (2014)
-
Serum appearance of anti-p53 antibody in triple negative breast cancer
Breast Cancer (2012)
-
Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case–control study of 569 patients and 879 healthy controls
Molecular Biology Reports (2010)
-
Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients
Medical Oncology (2010)